Tandem t:slim X2 Insulin Pump Suspension Lifted

7th April 2021

The Therapeutic Goods Administration (TGA) suspension of the ARTG entry for the Tandem Diabetes Care t:slim X2 insulin pump has officially been lifted.

AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA and have now successfully addressed their concerns for the t:slim X2 insulin pump. For more information on what these concerns were and how they have been resolved, please visit the TGA website.

As of 1st April 2021, AMSL Diabetes are able to continue supply for all new t:slim X2 insulin pumps with Basal-IQ technology (version 6.4.1). Basal-IQ technology is compatible with the new Dexcom G6 CGM system. We strongly encourage all customers using the t:slim X2 insulin pump with Dexcom G5 Mobile to update their pump software to the latest available technology free of charge.

Users of the t:slim X2 insulin pump who meet the NDSS CGM Subsidy Initiative eligibility criteria can now have access to the fully subsidised Dexcom G6 CGM system through the program.

AMSL Diabetes and Tandem Diabetes Care are committed to the safety of their customers and to the quality of their products. We would like to thank all our customers and healthcare professionals for their continued support during this time whilst we worked to resolve this situation.

For more information, please contact our 24/7 Customer Care Team by emailing diabetes@amsl.com.au or calling 1300 851 056. Or alternatively, contact your local AMSL Diabetes Representative.